

# Cortellis clinical trial database trial summary statistic tables and figures

July 24, 2017

Table 1: Number of trials receiving NIH funding by presence of biomarker

	No funding	NIH funding	Total
No biomarker	85,657	1,840	87,497
Biomarker	57,295	2,198	59,493
Total	142952	4,038	146990

Table 2: Number of trials receiving NIH funding by presence of biomarker and location

	(1) All Trials	(2) US Trials	(3) Non-US Trials
Number of trials receiving funding			
No biomarker	1840 (42.4)	1691 (39.9)	50 (7.1)
Biomarker	2198 (46.0)	2053 (43.4)	64 (8.0)
Percent of trials receiving funding			
No biomarker	2.1 (0.05)	6.0 (0.14)	0.1 (0.02)
Biomarker	3.7 (0.08)	8.5 (0.18)	0.2 (0.03)
Observations	146990	52601	69857

Table 3: Number of trials receiving NIH funding by presence of biomarker and phase

	(1) All Trials	(2) Phase I	(3) Phase II	(4) Phase III
Number of trials receiving funding				
No biomarker	1840 (42.4)	647 (25.2)	976 (30.8)	217 (14.6)
Biomarker	2198 (46.0)	880 (28.9)	1157 (33.3)	161 (12.6)
				D
Percent of trials receiving funding				
No biomarker	2.1 (0.05)	2.0 (0.08)	2.7 (0.08)	1.1 (0.07)
Biomarker	3.7 (0.08)	4.9 (0.16)	4.2 (0.12)	1.2 (0.09)
Observations	146990	49487	64155	33348

Table 4: Percent of trials receiving NIH funding by biomarker role

	(1) All Trials	(2) No Biomarker	(3) Biomarker present	(4) Disease	(5) Therapeutic effect	(6) Toxic effect	(7) Role not determined
Percent receiving funding	2.7 (0.0)	2.1 (0.0)	3.7 (0.1)	5.8 (0.2)	3.7 (0.1)	2.1 (0.2)	3.3 (0.9)
Observations	146990	87497	59493	12235	48973	7043	359

Standard errors in parentheses

Trials may employ multiple biomarkers with one or more biomarker roles.

Table 5: Trials by Phase

	Trial count	Percent of all Phase I-III
Phase 1 Clinical	35,931	24.4
Phase 1/Phase 2 Clinical	11,514	7.8
Phase 1a Clinical	336	0.2
Phase 1b Clinical	1,706	1.2
Phase 2 Clinical	54,724	37.2
Phase 2/Phase 3 Clinical	5,699	3.9
Phase 2a Clinical	2,143	1.5
Phase 2b Clinical	1,589	1.1
Phase 3 Clinical	32,042	21.8
Phase 3a Clinical	125	0.1
Phase 3b Clinical	1,181	0.8
Total	146990	100.0

Table 6: Average trial duration in months

End year	Duration (months)	# of trials with nonmissing duration
2000	32.4	267
2001	36.8	350
2002	36.6	447
2003	32.5	709
2004	35.8	857
2005	34.2	1,175
2006	34.0	1,543
2007	34.3	2,046
2008	31.2	2,401
2009	32.9	2,615
2010	35.1	2,651
2011	36.5	2,761
2012	38.4	2,898
2013	40.2	2,763
2014	39.6	2,945
2015	41.8	2,798
2016	41.4	3,098
Observations	32324	

Table 7: Selected averages by NIH funding status

	All trials		No NIH funding		NIH funding	
	Average	Standard error	Average	Standard error	Average	Standard error
US trial	0.49	0.0017	0.47	0.0017	0.97	0.0031
Biomarker used	0.47	0.0017	0.47	0.0017	0.54	0.0092
Subjects enrolled	256.2	18.2	260.0	18.8	143.7	21.7
Duration	36.6	0.11	35.8	0.11	62.1	0.76

Table 8: Percent of trials receiving NIH funding by presence of biomarker: All trials

	(1)	(2)	(3)
	All trials	No biomarker	Biomarker
1995	3.8	3.5	5.7
1996	4.0	3.5	7.6
1997	5.8	5.4	8.3
1998	4.8	4.4	6.2
1999	4.9	4.4	6.9
2000	5.6	4.8	8.5
2001	4.7	3.9	7.8
2002	4.0	3.3	6.3
2003	3.9	3.4	5.2
2004	4.0	3.1	6.2
2005	3.9	2.8	6.3
2006	3.5	2.4	5.9
2007	2.8	1.8	4.7
2008	2.9	1.9	4.5
2009	2.8	1.9	4.1
2010	2.2	1.1	3.5
2011	1.9	1.0	2.9
2012	1.7	0.9	2.4
2013	2.2	1.8	2.6
2014	2.2	1.5	2.8
2015	2.2	1.3	2.9
2016	1.9	1.1	2.7

Table 9: Percent of trials receiving NIH funding by presence of biomarker: US trials

	(1)	(2)	(3)
	All trials	No biomarker	Biomarker
1995	12.2	12.4	11.1
1996	9.8	10.0	9.2
1997	13.1	12.9	13.6
1998	10.7	10.9	10.1
1999	8.6	8.1	10.3
2000	12.7	12.1	14.3
2001	9.9	8.6	13.1
2002	9.1	8.4	10.6
2003	8.7	8.6	8.9
2004	8.8	7.3	11.8
2005	9.1	7.1	12.7
2006	8.3	6.1	12.0
2007	6.9	4.7	10.0
2008	6.6	4.6	9.2
2009	6.8	4.9	9.1
2010	5.6	3.4	7.6
2011	4.9	2.8	6.5
2012	4.8	3.4	5.9
2013	6.0	5.6	6.3
2014	5.3	4.1	6.2
2015	5.8	3.7	7.1
2016	6.0	3.9	7.6

Table 10: Percent of trials receiving NIH funding by phase

	Phase I-III	Phase I	Phase II	Phase III	Number of trials
Start year					
main					
1995	3.8	2.1	6.0	3.3	866.0
1996	4.0	3.5	4.8	3.4	970.0
1997	5.8	5.6	8.0	3.0	1322.0
1998	4.8	5.3	6.0	1.9	1704.0
1999	4.9	4.1	6.9	2.9	2407.0
2000	5.6	7.3	6.1	2.6	2625.0
2001	4.7	4.7	5.7	3.3	2993.0
2002	4.0	3.9	5.0	2.5	3718.0
2003	3.9	5.1	4.1	2.1	4190.0
2004	4.0	4.1	5.8	1.2	5216.0
2005	3.9	4.3	4.9	1.6	6407.0
2006	3.5	4.0	4.7	1.0	7176.0
2007	2.8	3.2	3.7	0.7	7557.0
2008	2.9	3.3	3.6	0.9	8014.0
2009	2.8	3.5	3.2	0.8	8498.0
2010	2.2	2.7	2.5	0.8	8736.0
2011	1.9	2.0	2.4	0.7	8997.0
2012	1.7	2.1	2.0	0.2	9269.0
2013	2.2	2.7	2.8	0.3	9133.0
2014	2.2	3.1	2.3	0.5	9442.0
2015	2.2	2.6	2.5	0.8	10569.0
2016	1.9	2.7	1.9	0.6	12162.0







